Echocardiographic indicators of left ventricular myocardial dysfunction in lymphomas
AbstractLeft ventricular (LV) dysfunction assessed using routine echocardiography parameters in combination with global longitudinal strain (GLS) is often detected in patients with lymphomas not only during treatment but also before the start of anticancer therapy. In order to evaluate systolic function and LV strain in young individuals with Hodgkin’s (HL) and non-Hodgkin’s (NHL) lymphomas to identify markers of early myocardial dysfunction before and during treatment, 30 young patients with lymphomas (mean age 33.5 years) were examined, including 18 patients (60%) with HL and 12 patients (40%) with NHL. The control group consisted of 30 healthy individuals (mean age 29.5 years). In all patients, linear and volumetric LV parameters, as well as the ejection fraction (EF) and LV GLS were determined using echocardiography at baseline (before treatment) and in the early stages of chemotherapy (3 months). In both groups, the EF and GLS were within normal values, but were significantly lower in the main group (EF – 65.2 vs 68%, p=0.035; LV GLS 18.4 vs 22.6%, p<0.0001, in the main and control groups, respectively). No significant decrease in LV systolic function was found in patients of the main group at the early stages (3 months) of chemotherapy, just as no differences in EF and LV GLS were found in the HL and NHL groups. Thus, the LV GLS is the only parameter of subclinical myocardial dysfunction in patients with lymphomas available for clinical practice; it has borderline values even before the start of treatment, which may reflect the primary myocardial damage in oncohematological diseases.
Keywords: left ventricular ejection fraction; global longitudinal myocardial deformation; cardiotoxicity; Hodgkin’s lymphoma; non-Hodgkin’s lymphoma
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Bartosh-Zelenaya S.Yu., Sazonova D.S., Naiden T.V., Aletdinova L.A., Pavlyuchenko E.S. Echocardiographic indicators of left ventricular myocardial dysfunction in lymphomas. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2025; 13 (1): 31–7. DOI: https://doi.org/10.33029/2309-1908-2025-13-1-31-37 (in Russian)
References
1. Moiseev V.S., Kobalava Zh.D., Moiseev S.V. Internal diseases with the basics of evidence-based medicine and clinical pharmacology. Moscow: GEOTAR-Media, 2010: 832 p. (in Russian)
2. Malignant neoplasms in Russia in 2017 (incidence and mortality). In: A.D. Kaprin, V.V. Starinsky, G.V. Petrova (eds). Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2018. (in Russian)
3. Thandra K.C., Barsouk A., Saginala K., Padala S.A., Barsouk A., Rawla P. Epidemiology of non-Hodgkin’s lymphoma. Med Sci (Basel). 2021; 9 (1): 5. DOI: https://doi.org/10.3390/medsci9010005 PMID: 33573146; PMCID: PMC 7930980.
4. Nabiałek-Trojanowska I., Jankowska H., Sławiński G., Dąbrowska-Kugacka A., Lewicka E. Echocardiographic findings in asymptomatic mediastinal lymphoma survivors years after treatment termination. J Clin Med. 2023; 12 (10): 3427. DOI: https://doi.org/10.3390/jcm12103427 PMID: 37240533; PMCID: PMC 10219019.
5. Munir F., Hardit V., Sheikh I.N., AlQahtani S., et al. Classical Hodgkin lymphoma: from past to future – a comprehensive review of pathophysiology and therapeutic advances. Int J Mol Sci. 2023; 24 (12): 10095. DOI: https://doi.org/10.3390/ijms241210095 PMID: 37373245; PMCID: PMC 10298672.
6. Yang H., Wright L., Negishi T., Negishi K., Liu J., Marwick T.H. Research to practice: assessment of left ventricular global longitudinal strain for surveillance of cancer chemotherapeutic-related cardiac dysfunction. JACC Cardiovasc Imaging. 2018; 11: 1196–201.
7. Smiseth O.A., Torp H., Opdahl A., Haugaa K.H., Urheim S. Myocardial strain imaging: how useful is it in clinical decision making? Eur Heart J. 2018; 37: 1196–207.
8. Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022; 23 (10): e333–465. DOI: https://doi.org/10.1093/ehjci/jeac106 DOI: https://doi.org/10.1093/ehjci/jead080 PMID: 36017575.
9. Polomski E.A., Heemelaar J.C., Krol A.D., et al. Impaired global longitudinal strain is associated with cardiovascular events in Hodgkin lymphoma survivors. Cancers (Basel). 2022; 14 (9): 2329. DOI: https://doi.org/10.3390/cancers14092329 PMID: 35565458; PMCID: PMC 9099469.
10. Militaru A., Zus S., Cimpean A.M., et al. Early diagnosis of cardiotoxicity in patients undergoing chemotherapy for acute lymphoblastic leukemia. Anticancer Res. 2019; 39 (6): 3255–64. DOI: https://doi.org/10.21873/anticanres.13467 PMID: 31177176.
11. Pavlovic M., Dordevic A., Haßfeld S., et al. Left ventricular mechanics in patients with hematological malignancies before initiation of chemo- and radiotherapy. Int J Cardiovasc Imaging. 2021; 37 (3): 881–7. DOI: https://doi.org/10.1007/s10554-020-02061-7 Epub 2020 Oct 12. PMID: 33044719.
12. Tadic M., Genger M., Baudisch A., et al. Left ventricular strain in chemotherapy-naive and radiotherapy-naive patients with cancer. Can J Cardiol. 2018; 34 (3): 281–7.
13. Akam-Venkata J., Kadiu G., Galas J., Aggarwal S. Pediatric malignancies: is the prechemotherapy left ventricular function normal? Echocardiography. 2019; 36 (9): 1727–35.
14. Berkowitz C., Dittus C. Diagnosis and management of AL amyloidosis due to B-cell non-Hodgkin lymphoma. Front Oncol. 2022; 12: 915420. DOI: https://doi.org/10.3389/fonc.2022.915420 PMID: 36591532; PMCID: PMC 9797846.
15. Cohen O.C., Ismael A., Pawarova B., et al. Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. Eur Heart J. 2022; 43 (4): 333–41. DOI: https://doi.org/10.1093/eurheartj/ehab507 PMID: 34472567.
16. Ma L., Wang Q., Li X., et al. Development of a risk assessment model for cardiac injury in patients newly diagnosed with acute myeloid leukemia based on a multicenter, real-world analysis in China. BMC Cancer. 2024; 24 (1): 132. DOI: https://doi.org/10.1186/s12885-024-11847-0 PMID: 38273254; PMCID: PMC 10809495.